Navigation Links
FDA Approves Edarbi to Treat High Blood Pressure
Date:2/25/2011

SILVER SPRING, Md., Feb. 25, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Edarbi tablets (azilsartan medoxomil) to treat high blood pressure (hypertension) in adults.

(Logo:  http://photos.prnewswire.com/prnh/20090824/FDALOGO)

Data from clinical studies showed Edarbi to be more effective in lowering 24-hour blood pressure compared with two other FDA-approved hypertension drugs, Diovan (valsartan) and Benicar (olmesartan).

"High blood pressure is often called the 'silent killer' because it usually has no symptoms until it causes damage to the body," said Norman Stockbridge, M.D., Ph.D., director of the Division of Cardiovascular and Renal Drug Products in the FDA's Center for Drug Evaluation and Research. "High blood pressure remains inadequately controlled in many people diagnosed with the condition, so having a variety of treatment options is important."

Edarbi will be available in 80 milligram and 40 mg doses, with the recommended dose set at 80 mg once daily. The 40 mg dose will be available for patients who are treated with high-dose diuretics taken to reduce salt in the body.

Blood pressure is the force of blood pushing against the walls of the arteries as the heart pumps. If blood pressure rises and stays high over time, it can damage the body in many ways. Nearly 1 in 3 adults in the United States has high blood pressure, which increases the risks of stroke, heart failure, heart attack, kidney failure, and death. 

Edarbi is an angiotensin II receptor blocker (ARB) that lowers blood pressure by blocking the action of angiotensin II, a vasopressor hormone.

Adverse reactions reported by patients taking Edarbi in clinical trials were similar to those reported by those taking an inactive drug (placebo).

Edarbi has a boxed warning that says the use of the drug should be avoided in pr
'/>"/>

SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. FDA Approves EDARBI (azilsartan medoxomil) for the Treatment of Hypertension
2. FDA Approves Product to Prevent Bleeding in People With Rare Genetic Defect
3. FDA Approves First 3-D Mammography Imaging System
4. FDA Approves 1st Pacemaker Designed to Work Safely During Some MRI Exams
5. FDA Approves Hologics Makena™ (Formerly Referred to as Gestiva™) Pharmaceutical
6. FDA Approves Drug to Reduce Risk of Preterm Birth in At-Risk Pregnant Women
7. FDA Approves Makena™, the First and Only Treatment to Reduce the Risk of Preterm Birth in Women With a Singleton Pregnancy Who Have a History of Singleton Spontaneous Preterm Birth
8. FDA Approves Viibryd to Treat Major Depressive Disorder
9. FDA Approves Head Lice Treatment for Children and Adults
10. FDA Approves Opioid Analgesic to Help Cancer Patients Manage Pain
11. VIDEO from Endo Pharmaceuticals Available on thenewsmarket.com: FDA Approves New Treatment for Low Testosterone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... DUBLIN , Sept. 29, 2014 Research ... "Cardiac Pacemakers - Global Trends, Estimates and Forecasts, 2012-2018" ... sector is projected to reach US$5.7 billion by 2016. The ... global market share while Europe claims ... fastest growing region with a CAGR of 11.4% driving a ...
(Date:9/29/2014)... 2014  Guerbet, a pioneer in the field ... a Drug Shortage Assistance Award from the U.S. ... preventing or alleviating a drug shortage. ... to the shortage of Ethiodol (ethiodized oil) injection, ... post-approval supplements to restart manufacturing with acceptable compliance ...
(Date:9/29/2014)... , Sept. 29, 2014 Adaptive ... Next Generation Sequencing to profile the adaptive immune ... Scientific Advisory Board to provide strategic and clinical ... suite of assays in the diagnosis and monitoring ... focus of the SAB will be to support ...
Breaking Medicine Technology:Global Cardiac Pacemakers - Trends, Estimates and Forecasts to 2018 2Global Cardiac Pacemakers - Trends, Estimates and Forecasts to 2018 3Global Cardiac Pacemakers - Trends, Estimates and Forecasts to 2018 4Global Cardiac Pacemakers - Trends, Estimates and Forecasts to 2018 5Guerbet Receives FDA's Drug Shortage Assistance Award: Recognized for contributions to address a shortage of Ethiodol (ethiodized oil) injection 2Adaptive Biotechnologies Announces the Formation of a Hematologic Malignancies Scientific Advisory Board 2Adaptive Biotechnologies Announces the Formation of a Hematologic Malignancies Scientific Advisory Board 3
(Date:9/29/2014)... retrospective study led by researchers at Brigham and ... colonoscopies for colorectal cancer screening and surveillance. The ... intervals than established guidelines support, and these recommendations ... , "Our study shows that a high percentage ... resulting in use of scarce health care resources ...
(Date:9/29/2014)... Atlantic NeuroSurgical Specialists (ANS) brain ... to celebrate their strides in their fight against brain cancer. ... at their Morristown office. , The annual BBQ has grown ... a place where patients can find love, hope and support ... and activities were enjoyed by guests, including a dunk tank ...
(Date:9/29/2014)... September 30, 2014 NAPW ... as a 2014 Professional Woman of the Year. Ms. ... in home healthcare. As the largest networking organization of ... and profession, the National Association of Professional Women is ... and nearly 300 Local Chapters. , “I love the ...
(Date:9/29/2014)... NY (PRWEB) September 30, 2014 ... B.S.N., Clinical Manager Specialist, as a 2014 Professional Woman ... prestigious distinction for leadership in clinical care. As the ... spanning virtually every industry and profession, the National Association ... with over 600,000 members and nearly 300 Local Chapters. ...
(Date:9/29/2014)... September 30, 2014 Top10BestSEOHosting.com is ... reviews about hosting products. It is headed by ... experience. The site offers research-based information and factual ... suppliers in the current market. , Top10BestSEOHosting.com ... announced that GoDaddy ( http://www.top10bestseohosting.com/go/GoDaddy.com/ ) and Bluehost ...
Breaking Medicine News(10 mins):Health News:Endoscopists recommend frequent colonoscopies, leading to its overuse 2Health News:Local Brain Tumor Foundation, ANS Center of Hope, Celebrates its Brain Cancer Patients 2Health News:National Association of Professional Women Announces Carol A. Stormer, Home Health Occupational at LHC GroupTherapist, a 2014 Professional Woman of the Year 2Health News:National Association of Professional Women Announces Sarah Shiermeister, Clinical Manager Specialist at Gentiva Health Services, a 2014 Professional Woman of the Year 2Health News:Top10BestSEOHosting.com: New Reviews for Linux Web Hosting Suppliers Available Online 2
... standard for grading, staging and "stad-ging" the chronic liver ... acquiring new knowledge on the liver pathology. Demand for ... in liver biopsy samples has been fuelled by the ... molecules on the lesions characterising the histological patterns of ...
... 31 /PRNewswire-Asia-FirstCall/ -- China Medical Technologies,Inc. (the ... leading China-based medical device,company that develops, manufactures ... that the Company has completed the previously,announced ... tumor therapy system,business (the "HIFU Business") to ...
... in Near Term Continue Trading Under the Ticker ... HAXS ) and BPO Management Services, Inc., ... focused on serving middle-market enterprises, today jointly announced ... the previously announced merger in which BPOMS will ...
... Dec. 30 Scantek Medical, Inc. (Pink ... it filed a voluntary petition in the United States ... of the United States Code. Scantek also announced ... BreastCare(TM)/BreastAlert(TM) Differential Temperature Sensor product ("BreastCare") to a medical ...
... CAMBRIDGE, Mass., Dec. 30 Biopure Corporation (Nasdaq: ... has advised the U.S. Naval Medical Research Center ("NMRC") by ... Biopure,s product Hemopure [hemoglobin glutamer - 250 (bovine)], under a ... As previously announced, the Navy had filed a protocol ...
... Dec. 30 Biopure Corporation (Nasdaq: BPUR ... The NASDAQ Stock Market stating that NASDAQ has again ... value requirements for continued listing, thereby extending the Company,s ... these rules is scheduled to resume on Monday, April ...
Cached Medicine News:Health News:A rigorous method for liver biopsy 2Health News:China Medical Technologies Announces the Completion of the Sale of its HIFU Business 2Health News:China Medical Technologies Announces the Completion of the Sale of its HIFU Business 3Health News:China Medical Technologies Announces the Completion of the Sale of its HIFU Business 4Health News:China Medical Technologies Announces the Completion of the Sale of its HIFU Business 5Health News:Healthaxis and BPO Management Services, Inc. Announce Closing of Merger 2Health News:Healthaxis and BPO Management Services, Inc. Announce Closing of Merger 3Health News:Scantek Medical Files for Chapter 11 Voluntary Bankruptcy and Receives Orders for the Sale of BreastCare(TM) 2Health News:U.S. Navy Requested Operations Trial on FDA Hold 2Health News:U.S. Navy Requested Operations Trial on FDA Hold 3Health News:Biopure Receives Extension of Time to Regain NASDAQ Listing Compliance 2
... Catalyst system introduces a new ... to microsurgical instrumentation. It has ... design with advanced microcomputer control ... to operate with a full ...
The Storz Premiere comes as anterior, posterior and anterior/posterior combo. The combo provides the following modes irrigation, irrigation/aspiration, vitrectomy, and illumination....
... Horizon Phacoemulsification System is ... surgical system. Lightweight and ... performance and features in ... also provides all modes ...
Compact ultrasonic phacoemulsification system....
Medicine Products: